CML treatment results in Slovenia in the era of tirozin kinaze inhibitors
Background: Chronic myeloid leukemia (CML) is a malignant myeloproliferative disorder of hematopoietic stem cells. It is the first malignancy with a known specific chromosomal abnormality, the Philadelphia (Ph) chromosome t(9;22) (q34;q11), which has become a model in the research and treatment of m...
Main Authors: | Irena Preložnik Zupan, Tadej Pajič, Marjana Glaser, Tatjana Grmek Zemljič, Mateja Grat, Nataša Fikfak, Irena Bricman, Marija Čeh, Vlasta Petric, Milica Skamagkoulis |
---|---|
Format: | Article |
Language: | English |
Published: |
Slovenian Medical Association
2012-12-01
|
Series: | Zdravniški Vestnik |
Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/739 |
Similar Items
-
CHRONIC MYELOID LEUKAEMIA: EPIDEMIOLOGY DATA (2002–2007)
by: Irena Preložnik Zupan, et al.
Published: (2008-04-01) -
Imatinib plasma concentration – a new laboratory parameter for monitoring the treatment of Slovenian patients with chronic myeloid leukemia
by: Jernej Mlakar, et al.
Published: (2011-03-01) -
PRIMA1 ile lösemi hücrelerinde Bruton tirozin kinaz inhibisyonu aracılığı apoptoz uyarımı
by: Dara K. MOHAMMAD
Published: (2017-03-01) -
Severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review
by: Frosina Krstanovska, et al.
Published: (2011-05-01) -
SMERNICE ZA ODKRIVANJE IN ZDRAVLJENJE KRONIČNEMIELOIČNE LEVKEMIJE
by: Irena Preložnik Zupan, et al.
Published: (2008-04-01)